Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

(2020) Jacob P Laubach et al.   LANCET ONCOLOGY

Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma

(2018) Sishi Tang et al.   EXPERIMENTAL CELL RESEARCH

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

(2018) David S. Siegel et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management

(2018) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial

(2018) Elisabet E Manasanch et al.   Lancet Haematology

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

(2017) Philippe Moreau et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

(2017) Mark E. Issa et al.   Clinical Epigenetics

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

(2016) Jesús F San-Miguel et al.   Lancet Haematology

Panobinostat for the Treatment of Multiple Myeloma

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

(2014) Sridurga Mithraprabhu et al.   Epigenetics

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?

(2011) Antonio Palumbo et al.   BLOOD REVIEWS

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

(2008) M Pineda-Roman et al.   LEUKEMIA